SHEYLA FRANCO SANTANA: Open Payments
NPI 1760194203 · KISSIMMEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,066 in 98 payments from 21 companies in 2025. Trend: 2023 $598 · 2024 $2,308 · 2025 $2,066
Food & beverage: $2,066
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $208 |
| Janssen Biotech, Inc. | 9 | $204 |
| Madrigal Pharmaceuticals | 6 | $188 |
| Phathom Pharmaceuticals, Inc. | 9 | $185 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $147 |
| Ardelyx, Inc. | 5 | $117 |
| Gilead Sciences, Inc. | 1 | $114 |
| Ipsen Biopharmaceuticals, Inc | 3 | $82 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
Products named: TREMFYA, REZDIFFRA, VOQUEZNA, Linzess, ENTYVIO, XIFAXAN, CREON, IBSRELA.
Industry payments across FL — which companies pay providers there.
